Cara Therapeutics (CARA) Misses Q4 EPS by 3c

Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.43), $0.03 worse than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
• Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained